Paediatric age groups display important differences in host biology, predisposing conditions, epidemiology and presentation of fungal infections relative to the adult population. During the past decade, several new antifungal agents have been developed. Although not all of these agents are yet approved for children, the paediatric development of antifungal agents has moved forwards in an exemplary manner.
Introduction
Invasive fungal infections have evolved into important causes of morbidity and mortality in children with severe underlying illnesses. Irrespective of age and underlying condition, these infections remain difficult to diagnose, and responses to treatment depend on early diagnosis and prompt initiation of appropriate treatment. Apart from a better understanding of both the pharmacology and clinical indications of existing antifungal agents, recent years have witnessed the development of new broad-spectrum triazoles and the advent of the new class of echinocandins ( Fig. 1) . Children, in particular neonates and young infants, represent a unique patient population, in particular with regard to the disposition of antifungal agents and safety issues; however, antifungal pharmacodynamics may also be different, as emerging data on treatment approaches for central nervous system infections in premature neonates suggest. This article provides a brief update on the pharmacokinetics, safety and dosing of antifungal agents in paediatric patients, their clinical indications in the management of opportunistic fungal infections, and the current status of regulatory approval, with a focus on recent developments.
Established Antifungal Agents Amphotericin B deoxycholate
The pharmacokinetics of amphotericin B deoxycholate in paediatric patients are characterized by high inter-individual variability, but are not different from those observed in adults [1] . Infusion-related reactions, although rarely observed in neonates, and, even more, nephrotoxicity often limit treatment with amphotericin B deoxycholate [2] [3] [4] [5] [6] [7] [8] . In countries where alternative options are available, few indications are therefore left for antifungal treatment with amphotericin B deoxycholate. These include neonatal invasive candidiasis and induction therapy for cryptococcal meningitis. The recommended daily dosage in these settings ranges from 0.7 to 1.0 mg/kg daily administered over 2-4 h as tolerated; treatment should be started at the full target dosage with careful clinical monitoring.
Lipid formulations of amphotericin B
The lipid formulations of amphotericin B (amphotericin B colloidal dispersion (Amphocil or Amphote), amphotericin B lipid complex (Abelcet) and liposomal amphotericin B (AmBisome) allow for the safe delivery of higher dosages of the parent compound [9] . Each of the lipid formulations possesses distinct physicochemical and pharmacokinetic properties. Whether and how these distinct features translate into different pharmacodynamics in vivo is not well characterized.
The available pharmacokinetic and safety data for the lipid formulations of amphotericin B in paediatric age groups indicate no fundamental differences relative to the adult population [4, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] (48th ICAAC, Abstract A-005, Walsh T, 2008) (Table 1) . Taken together, the lipid formulations have less renal toxicity as defined by development of azotaemia than conventional amphotericin B; distal tubular toxicity also may be somewhat reduced. Infusion-related side effects of fever, chills and rigor are substantially less frequent with liposomal amphotericin B only, whereas the infusion-related reactions of amphotericin B colloidal dispersion and amphotericin B lipid complex appear to be similar to those of amphotericin B deoxycholate. Mild increases in serum bilirubin and alkaline phosphatase can be observed with all three formulations, and mild increases in serum transaminases with liposomal amphotericin B [9, 22] .
Currently, amphotericin B colloidal dispersion is licensed for treatment of patients with invasive aspergillosis refractory to, or who are intolerant to, amphotericin B deoxycholate, and amphotericin B lipid complex for treatment of patients with invasive Candida and Aspergillus infections refractory to, or who are intolerant to, amphotericin B deoxycholate; amphotericin B lipid complex may also be indicated for firstline treatment of zygomycosis [22] . Liposomal amphotericin B has approved first-line indications for empirical therapy of persistently neutropenic patients and for treatment of invasive mycoses, including invasive aspergillosis [23] and invasive candidiasis [24] . The recommended therapeutic dosages are 3-4 mg/kg per day for amphotericin B colloidal dispersion, 5 mg/kg daily for amphotericin B lipid complex, and 3 (to 5) mg/kg daily for liposomal amphotericin B [22] . The therapeutic dosage for treatment of zygomycosis should not be <5 mg/kg daily. As for to amphotericin B deoxycholate, treatment should be started with the full target dosage at the infusion rate recommended by the manufacturer.
5-Fluorocytosine
5-Fluorocytosine is a fungus-specific synthetic base analogue that has useful antifungal activity against Candida and Cryptococcus species [22, 25] . An established indication for 5-fluorocytosine is its use in combination with amphotericin B deoxycholate for induction therapy for cryptococcal meningitis [26, 27] . The combination with amphotericin B may also be an option for the treatment of Candida infections involving deep tissues [25] including Candida meningitis [28] [29] [30] ; however, the optimal management of Candida meningitis and meningoencephalitis is unknown [31] .
Although separate pharmacokinetic data for infants and children are lacking, extreme inter-individual variability in clearance and distribution volume has been reported in neonates [32] . Although recent analyses of therapeutic drug monitoring (TDM) data in children and pharmacokinetic bridging models suggest that lower dosages may be more appropriate [33, 34] , the approved starting dosage of 100 mg/ kg daily divided into three or four doses is currently recommended for both adults and children. TDM is advised; peak plasma levels between 40 and 60 lg/mL correlate with antifungal activity, but are seldom associated with marrow toxicity [35] .
Antifungal triazoles
The antifungal triazoles have become an important component of the antifungal armamentarium. Whereas fluconazole and itraconazole have been available for more than a decade, voriconazole and posaconazole have entered clinical practice only recently [25] (Fig. 2) .
Fluconazole. With the exception of premature neonates, where clearance may be decreased during the first days of life, paediatric patients tend to have greater normalized plasma clearance and a shorter half-life than adults [36] [37] [38] [39] ( Table 2) . Therefore, relative to weight, higher dosages are required in children to achieve comparable exposures. In paediatric patients, at dosages of up to 12 mg/kg daily, fluconazole is generally well tolerated [40] . The most common reported side effects include gastrointestinal disturbances (8%), increases in hepatic transaminases (5%) and skin reactions (1%); toxicity-related discontinuations occur in approximately 3% of patients [40] . Severe side effects, including relevant hepatotoxicity and exfoliative skin reactions, have been reported anecdotally [25] .
Fluconazole may be used for invasive Candida infections caused by susceptible organisms in paediatric patients of all ages who are in a stable condition and who have not received prior azole therapy [22, [41] [42] [43] [44] [45] [46] [47] . The recommended dosage range beyond the neonatal period is 6-12 mg/kg daily; in view of the faster clearance rate and the absence of population pharmacokinetics, however, 12 mg/kg daily may be the most appropriate dosage. For infants, populationbased pharmacokinetics and Monte Carlo simulation showed that for the treatment of invasive candidiasis, a dose of at least 12 mg/kg daily in the first 90 days after birth is needed Further potential therapeutic and prophylactic indications for fluconazole, including those for cryptococcal disease, are similar to those in adults. In low-birthweight infants, fluconazole has been shown to reduce Candida infections [49, 50] ; on the basis of these studies, fluconazole prophylaxis is a valid option for centres with a high frequency (>10%) of invasive Candida infections in premature infants of <1000 g birthweight or in the setting of a nosocomial outbreak with a fluconazolesusceptible Candida species. Population pharmacokinetics and Monte Carlo simulation support a dose of 3 or 6 mg/kg twice weekly during the first 42 days of life for early prevention of candidiasis in 23-29-week infants, and a 6 mg/kg dose every 72 h or 3 mg/kg daily for late prevention [39, 48] .
Itraconazole. The safety and pharmacokinetics of cyclodextrin itraconazole oral solution in immunocompromised paediatric patients ‡2 years of age have been studied in two phase II clinical trials [51, 52] in children with cancer, liver transplantation or human immunodeficiency virus infection who received the compound for treatment of oropharyngeal candidiasis or as prophylaxis. On the basis of safety and efficacy, a dosage of 2.5 mg/kg twice daily was recommended for the treatment of oropharyngeal candidiasis [52] . Population-based pharmacokinetics in paediatric cystic fibrosis and allogeneic bone marrow transplant patients receiving the oral solution or the capsule formulation as antifungal prophylaxis, however, suggest a starting dose of 5 mg/kg twice daily and TDM to maintain a target trough level of >0.5 lg/ mL [53] . Information on the intravenous hydroxypropyl-bcyclodextrin formulation is limited to a single-dose pharmacokinetic study in 33 children who received itraconazole at 2.5 mg/kg over 1 h. There was no safety issue, and analysis of pharmacokinetic parameters suggests that the compound can be administered with a weight-normalized dosing approach [54] .
Vomiting (12%), abnormal liver function tests (5%) and abdominal pain (3%) were the most common adverse effects considered to be related to cyclodextrin itraconazole solution in an open study in 103 neutropenic paediatric patients who received the drug at 5 mg/kg daily for antifungal prophylaxis; 18% of patients withdrew from the study because of adverse events [55] . Safety data on the intravenous cyclodextrin formulation in paediatric patients are limited to a singledose pharmacokinetic trial [54] ; similarly, only anecdotal reports have been published on the use of itraconazole in the neonatal setting.
Therapeutic and prophylactic indications for itraconazole in the settings of superficial and invasive mycoses have been reviewed elsewhere [25] . Itraconazole is not approved for use in individuals <18 years of age, and can therefore only be used off-label. On the basis of published pharmacokinetic and safety data, the starting dosage range for the oral solution of itraconazole in paediatric patients beyond the neonatal period is 5 mg/kg daily in two divided doses. The recommended target trough level is >0.5 lg/mL of the parent itraconazole by HPLC [25] . Multiple-dose pharmacokinetic data for intravenous itraconazole are currently lacking; the dosage regimen utilized in the published adult studies is 200 mg twice daily for 2 days, followed by 200 mg daily for a maximum of 12 days [56] .
New Agents and Current Status of Paediatric Development New antifungal triazoles
Voriconazole. Voriconazole is a synthetic oral and parenteral antifungal triazole with activity against a wide spectrum of clinically important yeasts and moulds ( Fig. 2; Table 3 ). Voriconazole is currently approved for the treatment of invasive aspergillosis, fusariosis and scedosporiosis, and for the primary treatment of invasive candidiasis in non-neutropenic patients. For patients aged 12 years and above, the recommended intravenous dosages are 6 mg/kg twice daily on day 1, followed by 4 mg/kg twice daily; the oral dosages are 400 mg twice daily on day 1 (<40 kg, 200 mg twice daily), followed by 200 mg twice daily (<40 kg, 100 mg twice daily).
Paediatric patients 2-11 years of age have a higher capacity for elimination of voriconazole per kilogram of bodyweight than healthy adult volunteers, resulting in a lower, Data compiled from [57, 66] .
potentially non-therapeutic, exposure at similar dosages [57] . In vitro studies with liver microsomes suggest that this differential clearance is attributable to faster action of CYP2C19 and flavin-containing monooxygenase 3 in N-oxidizing voriconazole in children [58] . In the interim, an intra-individual dosage escalation study has been completed; on the basis of the population-based analysis of the dataset of this and the initial dose-finding study, an intravenous dosage of 7 mg/kg twice daily and an oral dosage of 200 mg twice daily (oral suspension) without loading dosages has been approved in the European Union for children 2-11 years of age [59] . A very recent population-based analysis in 46 patients with a median age of 12 years (range, 0.8-20.5 years) found a pharmacodynamic association between a voriconazole trough concentration of >1000 ng/ mL and survival; simulations predicted that an intravenous dose of 7 mg/kg or an oral dose of 200 mg twice daily would achieve a trough >1000 ng/mL in most patients, including those ‡12 years of age [60] . Taken together, these data raise questions, as in adults, about the optimal dose, the dosing target and the need for TDM of voriconazole in paediatric patients aged ‡2 years. It is of note that for children <2 years of age, no systematic pharmacokinetic data exist, so that dosing is empirical [61] . Data for larger cohorts of voriconazole-treated paediatric patients are quite limited. Of 58 immunocompromised children with invasive fungal infections, 26 (45%) had a complete or partial response; in four patients (7%), the drug was discontinued because of intolerance. A total of 23 patients had voriconazole-related adverse events, most commonly elevations of hepatic transaminases or bilirubin (n = 8), skin rash (n = 8), abnormal vision (n = 3) and photosensitivity reactions (n = 3) [62] . In a retrospective cohort study in 37 immunocompromised children and adolescents who received the drug for a mean duration of 174 days, grade I or II adverse events were observed in 19 patients (51%); the most frequent events included transient increases in hepatic transaminases (19) and transient visual disturbances (five). Four patients experienced grade III/IV adverse events, and in three (8%) the drug was permanently discontinued [63] . It is of note that, apart from more serious hepatic adverse events, a possible link between long-term use of voriconazole, immunosuppression and chronic phototoxicity with aggressive squamous cell carcinoma has been reported in adult and paediatric patients [64] . Further clinical trials in paediatric patients initiated by the manufacturer are currently underway to collect supportive data on dosing, safety and antifungal efficacy.
Posaconazole. Posaconazole is a novel oral antifungal triazole with potent and broad-spectrum activity against opportunistic, endemic and dermatophytic fungi in vitro ( Fig. 2; Table 3 ). Importantly, posaconazole also possesses activity against zygomycetes both in vitro and in vivo, distinguishing it from all available azoles [65] .
Posaconazole has been approved in the European Union in patients ‡18 years of age for second-line treatment of aspergillosis, fusariosis, chromoblastomycosis and coccidioidomycosis. In addition, posaconazole is approved for prophylaxis in high-risk patients with acute myeloid leukaemia/ myelodysplastic syndrome and in haematopoietic stem cell transplant patients with graft-versus-host disease. The recommended daily dosage for salvage treatment is 400 mg twice daily given with food; for patients not tolerating solid food, a dosage of 200 mg four times daily is recommended, preferably together with a nutritional supplement. The dosage for prophylaxis is 200 mg three times daily [65] .
The pharmacokinetics of posaconazole in paediatric patients <18 years of age have not yet been studied systematically. Limited data obtained in 12 paediatric subjects ‡8 years of age indicate no fundamental differences in trough plasma concentrations as compared with adults [66] . Successful salvage treatment with posaconazole has been reported in 5/11 and 6/10 paediatric subjects with invasive fungal infections, which appears to be similar to the outcome in the adult population (15th ECCMID, Abstract P774; 67, Blune J, 2005). A paediatric development programme has been initiated by the manufacturer to define dosages, safety and tolerance in paediatric patients beyond the neonatal period.
Echinocandin lipopeptides
The echinocandins are a distinct class of intravenous semisynthetic amphiphilic lipopeptides that act by inhibiting the synthesis of 1,3-b-D-glucan in the fungal cell wall. Over the past decade, three compounds with similar spectra, pharmacokinetics, safety and antifungal efficacies have been developed: anidulafungin (Eraxis), caspofungin (Cancidas) and micafungin (Mycamine) ( Fig. 3 ; Table 4 ).
Anidulafungin. Anidulafungin is licensed in the European Union for primary therapy in non-neutropenic adult patients ( ‡18 years of age) with invasive Candida infections. The recommended dose regimen consists of 100 mg (day 1, 200 mg), administered at a rate not exceeding 1.1 mg/min. A paediatric phase I/II multicentre study on the pharmacokinetics and safety of anidulafungin has been completed in 19 granulocytopenic children with cancer. Patients were divided into two age cohorts (2-11 and 12-17 years) and were enrolled into sequential groups to receive 0.75 or 1.5 mg/kg daily [68] . No drug-related serious adverse events were recorded. Pharmacokinetic parameters were similar across age groups and dosage cohorts, and similar to those in adult subjects. Following single and multiple daily doses of 0.75 and 1.5 mg/kg, plasma concentration data corresponded to those in adults following a daily 50-mg and 100-mg dose, respectively. The manufacturer's paediatric development programme is at an advanced stage.
Caspofungin. Caspofungin is licensed in the European Union for adult and paediatric patients, including neonates, for second-line therapy of invasive aspergillosis, for primary therapy in non-neutropenic patients with invasive Candida infections, and for empirical antifungal therapy in persistently febrile granulocytopenic patients. The recommended dose regimen in adults consists of a single 70-mg loading dose on day 1, followed by 50 mg daily thereafter, administered over 1 h [69] .
In children and adolescents 2-17 years of age, the pharmacokinetics and safety of caspofungin were investigated with [72] .
Caspofungin is well tolerated in paediatric patients. In the above-mentioned phase I/II dose-finding trials, none of the patients developed a serious drug-related adverse event or had the drug discontinued because of toxicity [70] [71] [72] . In a phase III comparative estimation trial with safety as the primary objective, 82 patients between the ages of 2 and 17 years with persistent fever and neutropenia were randomly assigned to receive caspofungin or liposomal amphotericin B (3 mg/kg daily) in a 2 : 1 ratio. Rates of drugrelated adverse events were similar (clinical, 48.2% vs. 46.2%; laboratory, 10.7% vs. 19.2%); serious drug-related adverse events occurred in 1.8% of caspofungin-treated and in 11.5% of amphotericin B-treated patients. Overall success rates were not different [18] . In the combined analysis of caspofungin safety in all five clinical registration trials involving 171 paediatric patients aged 1 week to 17 years, the most common drug-related adverse events were fever (11.7%), increased alanine transaminase (6.5%), and rash (4.7%); few events were serious (0.6%) or required treatment discontinuation (1.2%) [73] . A favourable safety profile has also been reported in immunocompromised paediatric patients who received the compound for various indications outside of clinical registration trials, mostly in combination with other antifungal agents [74, 75] , and in neonates with refractory invasive candidiasis [76, 77] .
Micafungin. Micafungin is licensed in the European Union for neonates, children and adults for the treatment of invasive candidiasis and as prophylaxis for Candida infections in patients with allogeneic haematopoietic stem cell transplantation and those with prolonged neutropenia; it is also licensed for the treatment of oesophageal candidiasis in individuals 16 years and older. The recommended dosage is 100 mg daily for invasive candidiasis (£40 kg bodyweight, 2 mg/kg) with the option of dose escalation to 200 mg daily or 4 mg/kg daily, 150 mg daily for oesophageal candidiasis (£40 kg, 3 mg/kg), and 50 mg daily (£40 kg, 1 mg/kg) for prevention.
The pharmacokinetics of micafungin have been studied in 70 children and adolescents in an open-label, sequential group, dose escalation study of empirical therapy in febrile granulocytopenic children aged 2-17 years. At dosages ranging from 0.5 to 3.0 mg/kg daily, the pharmacokinetics were linear and the pharmacokinetic parameters were similar to those observed in adults [78] . Population-based pharmacokinetic modelling of the data revealed that clearance in smaller children was higher than predicted on the basis of weight alone, requiring a relative dosage increase to ensure exposure comparable to that in older children; however, dosages of 2 and 4 mg/kg in the children achieved at least similar exposures as 100 and 200 mg, respectively, in adults [79] . The pharmacokinetics in neonates were explored in a phase I, single-dose, multicentre, open-label, sequential dose trial of micafungin (0.75, 1.5 and 3.0 mg/kg) in 18 premature infants weighing >1000 g. On average, the half-life was shorter and the clearance was more rapid than in older children and adults [80] . Population pharmacokinetic modelling of the neonatal pharmacokinetic data and Monte Carlo simulation suggest that a larger neonatal dose is required to produce drug exposure comparable to those predicted on the basis of weight in children and adults; additional population pharmacokinetics based on open-label pharmacokinetic studies with doses up to 15 mg/kg daily support a target dose of 10 mg/kg for neonates, particularly in view of the substantial risk of secondary brain involvement [81] [82] [83] [84] . Although the treatment results in the pivotal candidaemia study showed no sign of decreased efficacy at dosages between 2 and 4 mg/kg in this population [17] , we recommend a dose of at least 4 mg/kg in neonates with invasive candidiasis and a dose of 10 mg/kg in the case of central nervous system involvement.
The comparative safety of micafungin was investigated in the paediatric subpopulation of a double-blind, phase III trial in patients with invasive candidiasis or candidaemia. Patients were randomized to receive intravenous micafungin (2 mg/kg daily) or liposomal amphotericin B (3 mg/kg daily) for a minimum of 14 days. There was no difference in the success rates (69.2% vs. 74.1%). The incidence of serious adverse events (3.8% vs. 9.3%) and the rate of patients discontinuing therapy because of an adverse event (3.8% vs. 16.7%) were lower in micafungin-treated patients [17] . In a pooled analysis of adverse event data from six clinical trials including 296 patients (median daily dose, 1.7 mg/kg (range: 0.4-8.6 mg/kg); median treatment duration, 15 days (range: 1-425 days), 26.7% of patients had a treatment-related adverse event and Fluconazole may be given as antifungal prophylaxis in institutions with a substantial incidence (>5% to 10%) of invasive candidiasis in very low birthweight infants or in outbreak situations AML, acute myeloid leukaemia; ANC, absolute neutrophile count; CNS, central nervous system; EMA, European Medicines Agency; FDA, Food and Drug Administration; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GVHD, graft-versus-host disease; IFI, invasive fungal infection; MDS, myelodysplastic syndrome. a Modified from Dornbusch et al. [85] . For details on the selected treatment options, please consult the text.
2.4% had a treatment-related adverse events that led to treatment discontinuation. No trends were seen with respect to dose or duration of treatment, and the types and rates of events were similar to those observed in adults (47th ICAAC, Abstract M-1162, Avvieta A, 2007). In Europe, the Summary of Product Characteristics for micafungin recommends careful monitoring of liver function, and early discontinuation in the presence of significant and persistent elevation of alanine transaminase/aspartate transaminase values. It also recommends that micafungin treatment should be conducted with a careful risk-benefit assessment, particularly in patients with liver diseases or receiving concomitant hepatotoxic/genotoxic therapies (Mycamine SPC; http://www.ema.europa.eu/ena/index.jsp.curl =pages/medicines/human/medicines/000734/human_med_0009 (last accessed 14 May 2010)). This recommendation is based on exposure-dependent development of foci of altered hepatocytes (significant) and liver tumours (non-significant) in a long-term exposure model in rats. The human relevance of this finding is presently not known. Similar, comparable preclinical studies for anidulafungin and caspofungin are not in the public domain.
Conclusions
Paediatric age groups display important differences in host biology, predisposing conditions, epidemiology and presentation of fungal infections relative to the adult population. During the past decade, several new antifungal agents have been developed. Although not all of these agents are yet approved for children, the development of antifungal agents for paediatric use has moved forwards in an exemplary manner. Invasive fungal infections will remain important causes of morbidity and mortality in immunocompromised paediatric patients. Whereas the availability of new therapeutic options is an important advance, antifungal therapy has become increasingly complex (Table 5) , and a thorough understanding of the available antifungal armamentarium is essential for the successful management of the individual patient.
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